ArticleJournal of clinical microbiology2016
Epidemiology of Invasive Group A Streptococcal Disease in Alaska, 2001 to 2013.
Article in Journal of clinical microbiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.
- Invasive group A streptococcal disease in pregnant women and young children: a systematic review and meta-analysis.The Lancet. Infectious diseases · 2022Pooled it
- Article
- Risk and determinants of mortality associated with invasive group A streptococcus (iGAS) disease in Scotland: A national surveillance study.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2025Article
- Article
- Group A Streptococcus among American Indian Persons, White Mountain Apache Tribal Lands, United States, 2016-2019Emerging infectious diseases · 2025Article
- Successful Transition to Whole-Genome Sequencing and Bioinformatics to Identify Invasive Streptococcus spp. Drug Resistance, Alaska, USA.Emerging infectious diseases · 2025Article
- Strep A: challenges, opportunities, vaccine-based solutions, and economics.NPJ vaccines · 2024Review
- Identification of an immunodominant region on a group AVirulence · 2023Article
- Incidence and clinical and microbiological features of invasive and probable invasive streptococcal group A infections in children and adults in the Brussels-Capital Region, 2005-2020.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2023Article
- Increasing Incidence of Invasive Group A Streptococcus Disease in First Nations Population, Alberta, Canada, 2003-2017.Emerging infectious diseases · 2021Article
- Group A Streptococcal Toxic Shock Syndrome after a Routine Gynecological Procedure.Case reports in obstetrics and gynecology · 2021Article
- Disparate Effects of Invasive Group A Streptococcus on Native Americans.Emerging infectious diseases · 2020Article
- Cross-serotype protection against group A Streptococcal infections induced by immunization with SPy_2191.Nature communications · 2020Article
- Beta-Haemolytic Group A, C and G Streptococcal Infections in Southern Hungary: A 10-Year Population-Based Retrospective Survey (2008-2017) and a Review of the Literature.Infection and drug resistance · 2020Article
- Article
- Invasive group A Streptococcus disease in Australian children: 2016 to 2018 - a descriptive cohort study.BMC public health · 2019Article
- Risk for Invasive Streptococcal Infections among Adults Experiencing Homelessness, Anchorage, Alaska, USA, 2002-2015.Emerging infectious diseases · 2019Article
- A multi-center clinical investigation on invasive Streptococcus pyogenes infection in China, 2010-2017.BMC pediatrics · 2019Article
- Streptococcus pyogenes-purpura fulminans as an invasive form of group A streptococcal infection.Annals of clinical microbiology and antimicrobials · 2018Review
- Community outbreak of invasive group A streptococcus infection in Ontario, Canada.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Arctic Investigations Program (AIP) began surveillance for invasive group A streptococcal (GAS) infections in Alaska in 2000 as part of the invasive bacterial diseases population-based laboratory surveillance program. Between 2001 and 2013, there were 516 cases of GAS infection reported, for an overall annual incidence of 5.8 cases per 100,000 persons with 56 deaths (case fatality rate, 10.7%). Of the 516 confirmed cases of invasive GAS infection, 422 (82%) had isolates available for laboratory analysis. All isolates were susceptible to penicillin, cefotaxime, and levofloxacin. Resistance to tetracycline, erythromycin, and clindamycin was seen in 11% (n = 8), 5.8% (n = 20), and 1.2% (n = 4) of the isolates, respectively. A total of 51 emm types were identified, of which emm1 (11.1%) was the most prevalent, followed by emm82 (8.8%), emm49 (7.8%), emm12 and emm3 (6.6% each), emm89 (6.2%), emm108 (5.5%), emm28 (4.7%), emm92 (4%), and emm41 (3.8%). The five most common emm types accounted for 41% of isolates. The emm types in the proposed 26-valent and 30-valent vaccines accounted for 56% and 78% of all cases, respectively. GAS remains an important cause of invasive bacterial disease in Alaska. Continued surveillance of GAS infections will help improve understanding of the epidemiology of invasive disease, with an impact on disease control, notification of outbreaks, and vaccine development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.